- Home
- FWONA vs WAT Comparison
FWONA vs WAT Comparison
Compare FWONA & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FWONA
- WAT
- Stock Information
- Founded
- FWONA 1950
- WAT 1958
- Country
- FWONA United States
- WAT United States
- Employees
- FWONA N/A
- WAT N/A
- Industry
- FWONA Broadcasting
- WAT Biotechnology: Laboratory Analytical Instruments
- Sector
- FWONA Industrials
- WAT Industrials
- Exchange
- FWONA Nasdaq
- WAT Nasdaq
- Market Cap
- FWONA 22.3B
- WAT 17.8B
- IPO Year
- FWONA N/A
- WAT 1995
- Fundamental
- Price
- FWONA $90.89
- WAT $303.42
- Analyst Decision
- FWONA Strong Buy
- WAT Hold
- Analyst Count
- FWONA 2
- WAT 15
- Target Price
- FWONA $106.00
- WAT $377.80
- AVG Volume (30 Days)
- FWONA 85.7K
- WAT 1.0M
- Earning Date
- FWONA 08-07-2025
- WAT 08-04-2025
- Dividend Yield
- FWONA N/A
- WAT N/A
- EPS Growth
- FWONA N/A
- WAT 8.23
- EPS
- FWONA N/A
- WAT 11.02
- Revenue
- FWONA $3,513,000,000.00
- WAT $2,983,253,000.00
- Revenue This Year
- FWONA $17.41
- WAT $6.11
- Revenue Next Year
- FWONA $11.26
- WAT $6.44
- P/E Ratio
- FWONA N/A
- WAT $27.55
- Revenue Growth
- FWONA 2.48
- WAT 2.57
- 52 Week Low
- FWONA $66.26
- WAT $279.62
- 52 Week High
- FWONA $96.40
- WAT $423.56
- Technical
- Relative Strength Index (RSI)
- FWONA 44.93
- WAT 40.43
- Support Level
- FWONA $91.76
- WAT $279.62
- Resistance Level
- FWONA $95.40
- WAT $305.87
- Average True Range (ATR)
- FWONA 1.81
- WAT 11.02
- MACD
- FWONA -0.32
- WAT 0.04
- Stochastic Oscillator
- FWONA 3.43
- WAT 29.61
About FWONA Liberty Media Corporation Series A Liberty Formula One
Liberty Media Corp along with its subsidiaries is engaged in the media and entertainment industries in North America and the United Kingdom. The company owns interests in a high-quality portfolio of assets across the media, entertainment and sports industries. The company derives its maximum revenue from United Kingdom.
About WAT Waters Corporation
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.